The models test whether TNF-TNFR1 signaling blockade affects PD onset regardless of whether or not individuals have a background of severe systemic inflammation.38 Consequently, we do not exclude therapeutic benefits in individuals with certain underlying conditions, such as IBD. This evidence concerns the gene TNFRSF1A and Parkinson disease.